{"url_path":"/sec/sbfm/8-k/2026-09-11/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-09-11","source_url":"https://www.sec.gov/Archives/edgar/data/1402328/0001683168-26-007090-index.html","accession_number":"0001683168-26-007090","cik":"0001402328","ticker":"SBFM","issuer_name":"Sunshine Biopharma Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1402328/0001683168-26-007090-index.html","primary_entity_key":"0001402328","primary_entity_name":"Sunshine Biopharma Inc."},"word_count":113,"has_tables":true,"body_markdown":"**Item 8.01 Other Events.**\n\n** **\n\nAs of the date of filing of this report, due to\nrecent sales of Sunshine Biopharma Inc.’s (the “Company”) common stock under the Company’s previously disclosed\nat-the-market offering, the exercise price of the Company’s outstanding Series B Warrants has been reduced to $1.2046, subject to\nfurther adjustment as set forth under the Series B Warrants.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n 2 \n\n \n\n \n\n**SIGNATURES**\n\n** **\n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\nDated: September 11, 2026\n**SUNSHINE BIOPHARMA INC.**\n\n \n \n\n \n \n\n \nBy: /s/ Dr. Steve N. Slilaty                                           \n\n \n\nName: Dr. Steve N. Slilaty, Chief Executive Officer\n\n \n\n** **\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n 3"}